Nonvitamin K antagonist oral anticoagulants (NOACs): the tide continues to come in

Click to increase image sizeClick to decrease image size

Disclosure

Dr Blann declares hospitality, speaker fees, and research funds from Pfizer, Bayer, Daiichi-Sankyo and Boehringer-Ingelheim. The University of Birmingham Centre for Cardiovascular Sciences at City Hospital, Birmingham, recruits into anticoagulant trials. The author reports no conflicts of interest in this work.